Avidity Biosciences (RNA) Competitors $30.62 -1.02 (-3.22%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$32.36 +1.74 (+5.68%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, and BBIOShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines BridgeBio Pharma Avidity Biosciences (NASDAQ:RNA) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the media refer more to RNA or ITCI? In the previous week, Avidity Biosciences had 19 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 22 mentions for Avidity Biosciences and 3 mentions for Intra-Cellular Therapies. Avidity Biosciences' average media sentiment score of 0.48 beat Intra-Cellular Therapies' score of 0.25 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in RNA or ITCI? Intra-Cellular Therapies received 352 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.39% of users gave Avidity Biosciences an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformAvidity BiosciencesOutperform Votes17069.39% Underperform Votes7530.61% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Which has higher valuation and earnings, RNA or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$8.93M413.39-$212.22M-$3.00-10.21Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do analysts prefer RNA or ITCI? Avidity Biosciences currently has a consensus target price of $66.38, suggesting a potential upside of 116.80%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Do institutionals & insiders hold more shares of RNA or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, RNA or ITCI? Avidity Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Is RNA or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -2,772.45%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-2,772.45% -27.66% -24.56% Intra-Cellular Therapies -14.07%-9.93%-8.38% SummaryAvidity Biosciences beats Intra-Cellular Therapies on 10 of the 18 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.81B$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-10.638.9226.8419.71Price / Sales413.39253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book4.536.466.794.50Net Income-$212.22M$143.98M$3.23B$248.18M7 Day Performance5.70%2.03%1.53%0.20%1 Month Performance3.97%4.11%10.05%12.37%1 Year Performance3.38%-2.87%16.71%7.04% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences1.905 of 5 stars$30.62-3.2%$66.38+116.8%+3.8%$3.81B$8.93M-10.63190Options VolumeITCIIntra-Cellular Therapies0.8742 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.4285 of 5 stars$19.93+2.9%$39.17+96.5%-29.6%$12.78B$21.64B11.451,660Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.3254 of 5 stars$13.93+3.9%$17.00+22.1%+4.0%$11.62B$311.31B22.1724,800Positive NewsGap UpVTRSViatris2.0724 of 5 stars$8.96+2.2%$10.50+17.2%-22.6%$10.63B$14.33B-12.1137,000Trending NewsMRNAModerna4.5341 of 5 stars$25.70+6.0%$53.95+109.9%-82.0%$9.94B$3.14B-2.773,900Trending NewsQGENQiagen3.9903 of 5 stars$42.92+2.5%$48.42+12.8%-3.5%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.504 of 5 stars$154.43+2.1%$216.07+39.9%+28.7%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences2.1398 of 5 stars$10.99+3.3%$17.50+59.2%-2.8%$7.84B$122.59M-73.26860Positive NewsUpcoming EarningsRVMDRevolution Medicines4.3654 of 5 stars$41.88+3.6%$67.17+60.4%-2.3%$7.80B$742,000.00-11.67250Positive NewsBBIOBridgeBio Pharma4.5948 of 5 stars$35.68+4.4%$57.09+60.0%+12.2%$6.77B$127.42M-12.52400Positive NewsInsider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Moderna Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
